We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Raili Kauppinen (University Hospital of Helsinki, Finland) shares key findings and insights into the ENVISION study, which evaluated the efficacy and safety of givosiran, a subcutaneously administered RNA interference therapeutic targeting aminolevulinic acid synthase 1, in patients with acute hepatic porphyrias (ClinicalTrials.gov Identifier: NCT03338816). Questions 1. Could you give us a brief overview of acute […]
Hans-Christoph Diener (Medical Faculty of the University of Duisburg-Essen, Institute for Medical Informatics, Biometry and Epidemiology, Essen, Germany) talks to us about unmet needs in the treatment of chronic migraine and medication-overuse headache, and shares expert insight on the PROMISE-2 trial, which evaluated the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal […]
Always a pleasure to catch-up with Editorial Board member, Bengt Winblad (Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden), who chatted with us on several topics including emerging therapeutic targets for Alzheimer’s disease (AD) and the role of the FKBP51-Hsp90 complex in underlying pathophysiological processes. Questions 1. What are the most promising emerging therapeutic targets […]
Always a pleasure to catch-up with Editorial Board member, Bengt Winblad (Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden), who chatted with us on several topics including the recent resurrection of an investigational human monoclonal antibody targeting beta-amyloid for the treatment of early Alzheimer’s disease (AD). Question What is your opinion of the resurrection of […]
Nadine Attal (University Versailles Saint Quentin, Versailles, France) shared with us her expert opinion on the controversial topic of therapeutic cannabis for neuropathic pain. Questions 1. What advantages does cannabis offer compared to current pharmacological treatments for neuropathic pain? (0:05) 2. What can we conclude about the clinical evidence to date? (0:41) 3. What have […]
A pleasure speaking to editorial board member, Joaquim Ferreira (Faculty of Medicine, University of Lisbon, and Campus Neurológico Sénior, Torres Vedras, Portugal), as always! He shared his personal thoughts in these uncertain times on the likely long-lasting impact of COVID-19. Questions 1. What are your thoughts on the long-lasting impact of COVID-19 on medical education? […]
A pleasure speaking to editorial board member, Joaquim Ferreira (Faculty of Medicine, University of Lisbon, and Campus Neurológico Sénior, Torres Vedras, Portugal), as always! He shared his personal thoughts in these uncertain times on the likely long-lasting impact of COVID-19. Questions 1. What will be the lasting impacts on healthcare systems by the COVID-19 pandemic? […]
A pleasure catching up with our European Editorial Board member Stefan Evers (University of Münster, Germany). He spoke to us about miscellaneous idiopathic headache disorders, the topic of his presentation in the ‘Integrative Treatment of Idiopathic Headache Disorders’ session. Questions 1. What is covered by the term ‘miscellaneous idiopathic headache disorders’? (0:05) 2. What are […]
Stephanie J Nahas (Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA) kindly took the time to discuss with us pooled findings from phase 3 randomised controlled trials with fremanezumab, an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody treatment, specifically in older patients (≥60 years) with episodic or chronic migraine. Questions 1. How does the clinical […]
Get the latest clinical insights from touchNEUROLOGY